ADMA Biologics Reports Third-Quarter 2026 Financial Results
ADMA reported third-quarter 2026 revenue of $141.1 million, up 5% year over year. The supplied update also lists ASCENIV revenue of $12, with no unit or further context provided.
Story updates
09:09:50 PM UTC
SquawkNews
ADMA Biologics 3Q EPS 22c >ADMA
09:12:10 PM UTC
SquawkNews
Nov 04 (Reuters) - ADMA Biologics outlook FY revenue USD 530 million.
09:14:41 PM UTC
SquawkNews
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year3Q 2026 Adjusted Net Income(1) of $51.1 Million, Increasing 31% Year-over-Year3Q 2026 G…
09:14:56 PM UTC
SquawkNews
ADMA Biologics, Inc. (ADMA) Q3 Revenue Rises 5% to $141.1M; Adjusted Earnings Outlook Increased